Nama's AI scorecard currently rates Verastem Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does VSTM report earnings?

Verastem's next scheduled report is on Mar 3, 2027. Analysts expect EPS of -$0.39.

What is the VSTM price target?

The median analyst price target from 9 analysts is $18.00, with a range of $12.00 – $24.00.

Is VSTM Shariah compliant?

Nama's AAOIFI-style screen reads Verastem as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Verastem (VSTM)

Healthcare · Biotechnology · NASDAQ

Verastem (VSTM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.02B and a free-cash-flow yield of -25.2%. Over the most recent reported fiscal year, revenue grew 209.1%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 6, 2026.

Momentum

Middle · +4.2% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-78.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.02B
Trailing P/E	—
Price / book	15.3
Price / sales	11.7
FCF yield	-25.2%
Dividend yield	—
Gross margin	86.3%
Operating margin	-182.6%
Net margin	-231.6%
Revenue growth (YoY)	+209.1%
Revenue growth (3-yr annual)	+128.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

VSTM earnings

Next report: Mar 3, 2027 (Q4 2026, EPS estimate -$0.39). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.72	-$0.44	-63.6%	—
Q2 2026	Aug 6, 2026	-$0.31	-$0.45	+31.1%	$40.08M
Q1 2026	May 7, 2026	-$0.43	-$0.47	+8.5%	$18.67M
Q4 2025	Mar 4, 2026	-$0.46	-$0.50	+8.0%	$17.54M

VSTM analyst price target

Median target $18.00 from 9 analysts, ranging $12.00 – $24.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live VSTM data on Nama Insights →

VSTM FAQ

Is VSTM a buy?: Nama's AI scorecard currently rates Verastem Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does VSTM report earnings?: Verastem's next scheduled report is on Mar 3, 2027. Analysts expect EPS of -$0.39.
What is the VSTM price target?: The median analyst price target from 9 analysts is $18.00, with a range of $12.00 – $24.00.
Is VSTM Shariah compliant?: Nama's AAOIFI-style screen reads Verastem as Not Shariah Compliant. At least one of the three ratios or the industry test failed.